Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK Cell Therapy for Pancreatic Cancer
NCT06503497Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR NK cells in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang University. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicity at 2 years. Started Jul 2024; status: recruiting.
02
Drugs
NKG2D CAR NK cells
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06503497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503497.